Shangbay Capital Management Company, LLC
Emerging managerSEC exempt reporting adviser (venture capital exemption).
- HQ
- CA
ShangBay Capital is a venture capital firm focused on medical device, biotechnology, and healthcare technology companies. It invests through venture equity participation. Its team includes a founding managing partner, a managing partner, venture partners, associates, and an analyst. Portfolio companies include Nervonik, Ceribell, Zeto, Inquis Medical, Venova Medical, Zenflow, Tioga Cardiovascular, Flare Therapeutics, Neuro42, and Avation Medical.
New fund likely raising soon
The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Not stated | Not enough dated deals | Growth, Series B, Series A |
| Sectors | Healthtech, Digital health, Biotech, Medical devices | Not enough dated deals | Healthtech, Biotech, Medical devices |
| Regions | Not stated | Not enough dated deals | CA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2016 | 1 | Biotech, Healthtech |
| 2018 | 5 | Healthtech, Biotech, Medical devices |
| 2019 | 4 | Healthtech, Biotech, Medical devices |
| 2020 | 2 | Healthtech, Manufacturing, Medical devices |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2016 | 0 | 0 | 1 | 0 | 0 |
| 2017 | 0 | 0 | 0 | 0 | 0 |
| 2018 | 0 | 0 | 1 | 3 | 1 |
| 2019 | 0 | 0 | 0 | 1 | 2 |
| 2020 | 0 | 0 | 1 | 0 | 1 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| ShangBay Capital III, LLC | 2021 | $48.18M to $81.71M (Form D and SEC adviser filing) | Follow-ons only |
03 · People across funds
- William Dai, Founding Managing Partner
ShangBay Capital III, LLC (Named on Form D)
- Anna Roberts, Analyst
ShangBay Capital III, LLC (Team)
- Chaucer Shen, Managing Partner
ShangBay Capital III, LLC (Team)
- Erik T. Engelson, Venture Partner
ShangBay Capital III, LLC (Team)
- John Dai, Associate
ShangBay Capital III, LLC (Team)
- Michael Wallace, Venture Partner
ShangBay Capital III, LLC (Team)
- Olivia Sinkula, Associate
ShangBay Capital III, LLC (Team)
- Andy Weimin Dai, Senior Advisor
On the team page, not linked to a fund
- Cindy Costello, Director of Finance & Administration
On the team page, not linked to a fund
- Dr. Malcolm G. Munro, Senior Medical Advisor
On the team page, not linked to a fund
- Mel Dong, Senior Advisor
On the team page, not linked to a fund
- Robert Kamen, Senior Advisor
On the team page, not linked to a fund
- Yajun Xu, Ph.D., Senior Advisor
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.shangbaycapital.com
- https://www.shangbaycapital.com/contact
- https://www.shangbaycapital.com/news-and-events
- https://www.shangbaycapital.com/people
- https://www.shangbaycapital.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 25, 2026